Under physiological conditions, PRMT5 inhibition promotes osteoblast differentiation, restricts excessive proliferation, and influences chondrocyte development to maintain bone homeostasis; in pathological contexts, it reduces glycolysis, suppresses tumor growth, and impairs DNA repair, demonstrating therapeutic potential in bone tumors. Here, PRMT5 is linked to bone neoplasm.